Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management

AIDS and Behavior

Volumn 10, Issue 3, 2006, Pages 227-245

  Simoni, Jane M ^a   Kurth, Ann E ^a   Pearson, Cynthia R ^b   Pantalone, David W ^a   Merrill, Joseph O ^a   Frick, Pamela A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiretroviral; HIV AIDS; Medication adherence; Self report; Viral load

Indexed keywords

DATA ANALYSIS; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; NONHUMAN; PUBLICATION; REVIEW; RNA VIRUS; SELF REPORT; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; DISEASE MANAGEMENT; GUIDELINES; HUMANS; PATIENT COMPLIANCE; SELF DISCLOSURE;

EID: 33745277561     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-006-9078-6     Document Type: Review

References (109)

1. Alcoba, M., Cuevas, M. J., Perez-Simon, M. R., Mostaza, J. L., Ortega, L., Ortiz de Urbina, J., et al. (2003). Assessment of adherence to triple antiretroviral treatment including indinavir: Role of the determination of plasma levels of indinavir. Journal of Acquired Immune Deficiency Syndromes, 33(2), 253-258.
2. Aloisi, M. S., Arici, C., Balzano, R., Noto, P., Piscopo, R., Filice, G., et al. (2002). Behavioral correlates of adherence to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 31(Suppl 3), S145-S148.
3. Altice, F. L., Mostashari, F., and Friedland, G. H. (2001). Trust and the acceptance of and adherence to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 28(1), 47-58.
4. Ammassari, A., Antinori, A., Aloisi, M. S., Trotta, M. P., Murri, R., Bartoli, L., et al. (2004). Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics, 45(5), 394-402.
5. Antinori, A., Cozzi-Lepri, A., Ammassari, A., Trotta, M. P., Nauwelaers, D., Hoetelmans, R., et al. (2004). Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antiviral Therapy, 9(2), 291-296.
6. Amsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Chang, C. J., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33(8), 1417-1423.
7. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14(4), 357-366.
8. Bangsberg, D. R., Bronstone, A., and Hofmann, R. (2002). A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. AIDS Care, 14(1), 3-15.
9. Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Deeks, S. G., Perry, S., et al. (2003). High levels of adherence do not prevent accumulation of HIV drug resistanc mutations. AIDS, 17(13), 1925-1932.
10. Bangsberg, D. R., Hecht, F. M., Clague, H., Charlebois, E. D., Ciccarone, D., Chesney, M., et al. (2001). Provider assessment of adherence to HIV antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 26(5), 435-442.
11. Bangsberg, D. R., Moss, A. R., and Deeks, S. G. (2004). Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 53(5), 696-699.
12. Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Deeks, S. G., Perry, S., et al. (2003). High levels of adherence do not prevent accumulation of HIV drug resistant mutations. AIDS, 17, 1925-1932.
13. Barroso, P. F., Schechter, M., Gupta, P., Bressan, C., Bomfim, A., and Harrison, L. H. (2003). Adherence to antiretroviral therapy and persistence of HIV RNA in semen. Journal of Acquired Immune Deficiency Syndromes, 32(4), 435-440.
14. Bartlett, J. A. (2002). Addressing the challenges of adherence. Journal of Acquired Immune Deficiency Syndromes, 29(Suppl 1), S2-S10.
15. Bartlett, J. G., and Gallant, J. E. (2004). Medical management of HIV infection (2004 ed.). Baltimore, MD: Johns Hopkins Medicine Health Publishing Business Group.
16. Bova, C. A., Fennie, K. P., Knafl, G. J., Dieckhaus, K. D., Watrous, E., and Williams, A. B. (2005). Use of electronic monitoring devices to measure antiretroviral adherence: Practical considerations. AIDS and Behavior, 9(1), 103-110.
17. Brigido, L. F., Rodrigues, R., Casseb, J., Oliveira, D., Rossetti, M., Menezes, P., et al. (2001). Impact ot adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. AIDS Patient Care and STDS, 15(11), 587-593.
18. Caplan, R. D., Harrison, R. V., Wellons, R. V., and Frech, J. R. P. (1980). Social support and patient adherence: Experimental and survey findings. Ann Arbor, MI: Survey Research Center, University of Michigan.
19. Carrieri, P., Cailleton, V., Le Moing, V., Spire, B., Dellamonica, P., Bouvet, E., et al. (2001). The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. Journal of Acquired Immune Deficiency Syndromes, 28(3), 232-239.
20. Carrieri, M. P., Raffi, F., Lewden, C., Sobel, A., Michelet, C., Cailleton, V., et al. (2003). Impact of early versus late adherence to highly active antiretroviral therapy on immunovirological response: A 3-year follow-up study. Antiviral Therapy, 8(6), 585-594.
21. Catz, S. L., Kelly, J. A., Bogart, L. M., Benotsch, E. G., and McAuliffe, T. L. (2000). Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology, 19(2), 124-133.
22. Cederfjall, C., Langius-Eklof, A., Lidman, K., and Wredling, R. (2002). Self-reported adherence to antiretroviral treatment and degree of sense of coherence in a group of HIV-infected patients. AIDS Patient Care and STDS, 16(12), 609-616.
23. Cingolani, A., Antinori, A., Rizzo, M. G., Murri, R., Ammassari, A., Baldini, F., et al. (2002). Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS, 16(3), 369-379.
24. Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12(3), 255-266.
25. Cohn, S. E., Kammann, E., Williams, P., Currier, J. S., and Chesney, M. A. (2002). Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in acquired immunodeficiency syndrome. Clinical Infectious Diseases, 34(8), 1129-1136.
26. DiMatteo, M. R. (2004). Variations in patients' adherence to medical recommendations: A quantitative review of 50 years of research. Medical Care, 42(3), 200-209.
27. Dorz, S., Lazzarini, L., Cattelan, A., Meneghetti, F., Novara, C., Concia, E., et al. (2003). Evaluation of adherence to antiretroviral therapy in Italian HIV patients. AIDS Patient Care and STDs, 17(1),33.
28. Duong, M., Piroth, L., Peytavin, G., Forte, F., Kohli, E., Grappin, M., et al. (2001). Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: Relationship to virologic response. Clinical Infectious Diseases, 33(3), 386-392.
29. Duran, S., Peytavin, G., Carrieri, P., Raffi, F., Ecobichon, J. L., Pereira, E., et al. (2003). The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination. AIDS, 17(7), 1096-1099.
30. Duran, S., Saves, M., Spire, B., Cailleton, V., Sobel, A., Carrieri, P., et al. (2001). Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS, 15(18), 2441-2444.
31. Duran, S., Solas, C., Spire, B., Carrieri, M. P., Fuzibet, J. G., Costagliola, D., et al. (2001). 'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS, 15(8), 1075-1077.
32. Eldred, L., Wu, A., Chaisson, R., and Moore, R. (1998). Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18(2), 117-125.
33. Fong, O. W., Ho, C. F., Fung, L. Y., Lee, F. K., Tse, W. H., Yuen, C. Y., et al. (2003). Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Medicine, 4(2), 133-138.
34. Gao, X., Nau, D., Rosenbluth, S., Scott, V., and Woodward, C. (2000). The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care, 12(4), 387-398.
35. Garcia de Olalla, P., Knobel, H., Carmona, A., Guelar, A., Lopez-Colomes, J. L., and Cayla, J. A. (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes, 30, 105-110.
36. Geletko, S. M., Segarra, M., Mayer, K. H., Fiore, T. C., Bettencourt, F. A., Flanigan, T. P., et al. (1996). Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women. Antimicrobial Agents and Chemotherapy, 40(6), 1338-1341.
37. Gifford, A., Bormann, J., Shively, M., Wright, B., Richman, D., and Bozzette, S. (2000). Predictors of self-reported adherence and plasma HIV concentrates in patients on multi drug antiretroviral regimens. Journal of Acquired Immune Deficiency Syndromes, 23(5), 386-395.
38. Giordano, T. P., Guzman, D., Clark, R., Charlebois, E. D., and Bangsberg, D. R. (2004). Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clinical Trials, 5(2), 74-79.
39. Godin, G., Gagne, C., and Naccache, H. (2003). Validation of a self-reported questionnaire assessing adherence to antiretroviral medication. AIDS Patient Care and STDs, 17(7), 325.
40. Golin, C. E., Liu, H., Hays, R. D., Miller, L. G., Beck, C. K., Ickovics, J., et al. (2002). A prospective study of predictors of adherence to combination antiretroviral medication. Journal of General Internal Medicine, 17(10), 756-765.
41. Gordillo, V., del Amo, J., Soriano, V., and Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 13(13), 1763-1769.
42. Gordis, L. (1979). Conceptual and methodologic problems in measuring patient compliance. In D. W. T. R. B. Haynes and D. L. Sackett (Eds.), Compliance in health care (pp. 23-48). Baltimore, MD: Johns Hopkins University.
43. Goujard, C., Bernard, N., Sohier, N., Peyramond, D., Lançon, F., Chwalow, J., et al. (2003). Impact of a patient education program on adherence to HIV medication: A randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes, 34(2), 191-194.
44. Grossberg, R., Zhang, Y., and Gross, R. (2004). A time-to-prescription- refill measure of antiretroviral adherence predicted changes in viral load in HIV. Journal of Clinical Epidemiology, 57(10), 1107-1110.
45. Haubrich, R. H., Little, S. J., Currier, J. S., Forthal, D. N., Kemper, C. A., Beall, G. N., et al. (1999). The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS, 13, 1099-1107.
46. Ho, C. F., Fong, O. W., and Wong, K. H. (2002). Patient self-report as a marker of adherence to antiretroviral therapy. Clinical Infectious Diseases, 34(11), 1534-1535.
47. Hogg, R., Heath, K., Bangsberg, D. R., Yip, B., Press, N., O'shaughnessy, M. V., et al. (2002). Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS, 16, 1051-1058.
48. Horne, R., Buick, D., Fisher, M., Leake, H., Cooper, V., and Weinman, J. (2004). Doubts about necessity and concerns about adverse effects: Identifying the types of beliefs that are associated with non-adherence to HAART. International Journal of STD AIDS, 15(1), 38-44.
49. Hugen, P. W., Langebeek, N., Burger, D. M., Zomer, B., van Leusen, R., Schuurman, R., et al. (2002). Assessment of adherence to HIV protease inhibitors: Comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. Journal of Acquired Immune Deficiency Syndromes, 30(3), 324-334.
50. Ickovics, J. (1997). Measures of adhference. Paper presented at the Adherence to New HIV Therapies : A Research Conference, Washington, DC..
51. Ickovics, J. R., Cameron, A., Zackin, R., Bassett, R., Chesney, M., Johnson, V. A., et al. (2002). Consequences and determinants of adherence to antiretroviral medication: Results from Adult AIDS Clinical Trials Group protocol 370. Antiviral Therapy, 7(3), 185-193.
52. Ingersoll, K. (2004). The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care, 16(2), 199-211.
53. Kimmerling, M., Wagner, G., and Ghosh-Dastidar, B. (2003). Factors associated with accurate self-reported adherence to HIV antiretrovirals. International Journal of STD AIDS, 14(4), 281-284.
54. Kleeberger, C. A., Phair, J. P., Strathdee, S. A., Detels, R., Kingsley, L., and Jacobson, L. P. (2001). Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 26(1), 82-92.
55. Kitahata, M. M., Reed, S. D., Dillingham, P. W., Van Rompaey, S. E., Young, A. A., Harrington, R. D., et al. (2004). Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. International Journal of STD AIDS, 15(12), 803-810.
56. Knobel, H., Alonso, J., Casado, J., Collazos, J., Gonzalez, J., Ruiz, L, et al. (2002). Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS, 16, 605-613.
57. Knobel, H., Guelar, A., Carmona, A., Espona, M., Gonzalez, A., Lopez-Colomes, J. L., et al. (2001). Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care and STDs, 15, 193-199.
58. Knobel, H., Vallecillo, G., Guelar, A., Pedrol, E., Soler, A., Carmona, A., et al. (2004). Simplified therapy with zidovudine, lamivudine, and abacavir for very nonadherent, treatment-failing patients. HIV Clinical Trials, 5(2), 65-73.
59. Konkle-Parker, D. J. (2000). What is the best way to measure medication adherence? HIV Clinical Trials, 12(3), 11-12.
60. Laniece, I., Ciss, M., Desclaux, A., Diop, K., Mbodj, F., Ndiaye, B., et al. (2003). Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS, 17(Suppl 3), S103-S108.
61. Le Moing, V., Chene, G., Carrieri, M. P., Alioum, A., Brun-Vezinet, F., Piroth, L., et al. (2002). Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS, 16(1), 21-29.
62. Le Moing, V., Chene, G., Carrieri, M. P., Besnier, J. M., Masquelier, B., Salamon, R., et al. (2001). Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. Journal of Acquired Immune Deficiency Syndromes, 27(4), 372-376.
63. Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., Sanandaji, S., et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134(10), 968-977.
64. Lucas, G. M., Cheever, L. W., Chaisson, R. E., and Moore, R. D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes, 27(3), 251-259.
65. Lopez-Suarez, A., Fernandez-Gutierrez del Almo, C., Perez-Guzman, E., and Giron-Gonzalez, J. A. (1998). Adherence to the antiretroviral treatment in asymptomatic HIV-infected patients. AIDS, 12(6), 685-686.
66. Maggiolo, F., Ripamonti, D., Arici, C., Gregis, G., Quinzan, G., Camacho, G. A., et al. (2002). Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clinical Trials, 3(5), 371-378.
67. Mannheimer, S., Friedland, G., Matts, J., Child, C., and Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34(8), 1115-1121.
68. Martin, J., Sabugal, G. M., Rubio, R., Sainz-Maza, M., Blanco, J. M., Alonso, J. L., et al. (2001). Outcomes of a health education intervention in a sample of patients infected by HIV, most of them injection drug users: Possibilities and limitations. AIDS Care, 13(4), 467-473.
69. Martin-Fernandez, J., Escobar-Rodriguez, I., Campo-Angora, M., and Rubio-Garcia, R. (2001). Evaluation of adherence to highly active antiretroviral therapy. Archives of Internal Medicine, 161(22), 2739-2740.
70. Martin, J., Sabugal, G. M., Rubio, R., Sainz-Maza, M., Blanco, J. M., Alonso, J. L., et al. (2001). Outcomes of a health education intervention in a sample of patients infected by HIV, most of them injection drug users: Possibilities and limitations. AIDS Care, 13(4), 467-473.
71. Mathews, W. C., Mar-Tang, M., Ballard, C., Colwell, B., Abulhosn, K., Noonan, C., et al. (2002). Prevalence, predictors, and outcomes of early adherence after starting or changing antiretroviral therapy. AIDS Patient Care and STDS, 16(4), 157-172.
72. Melbourne, K. M., Geletko, S. M., Brown, S. L., Willey-Lessne, C., Chase, S., and Fisher, A. (1999). Medication adherence in patients with HIV infection: A comparison of two measurement methods. The AIDS Reader, 9(5), 329-338.
73. Miller, L. G., and Hays, R. D. (2000). Adherence to combination antiretroviral therapy: Synthesis of the literature and clinical implications. The AIDS Reader, 10(3), 177-185.
74. Miller, L. G., Hays, R. D. (2000). Measuring adherence to antiretroviral medications in clinical trials. HIV Clinical Trials, 1(1), 36-16.
75. Moatti, J. P., Carrieri, M. P., Spire, B., Gastaut, J. A., Cassuto, J. P., and Moreau, J. (2000). Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 Study Group. AIDS, 14(2), 151-155.
76. Morisky, D. E., Green, L. W., and Levine, D. M. (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care, 24(1), 67-74.
77. Murri, R., Ammassari, A., De Luca, A., Cingolani, A., Marconi, P., Wu, A. W., et al. (2001). Self-reported nonadherence with antiretroviral drugs predicts persistent condition. HIV Clinical Trials, 2(4), 323-329.
78. Nieuwkerk, P., Gisolf, F., Sprangers, M., and Danner, S. (2001). Adherence over 48 weeks in an antiretroviral clinical trial: Variable within patients, affected by toxicities and independently predictive of virological response. Antiviral Therapy, 6(2), 97-103.
79. Nieuwkerk, P. T., and Oort, F. J. (2005). Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysis. Journal of Acquired Immune Deficiency Syndromes, 38(4), 445-448.
80. Nieuwkerk, P. T., Sprangers, M. A., Burger, D. M., Hoetelmans, R. M., Hugen, P. W., Danner, S. A., et al. (2001). Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Archives of Internal Medicine, 161(16), 1962-1968.
81. Oyugi, J. H., Byakika-Tusiime, J., Charlebois, E. D., Kityo, C., Mugerwa, R., Mugyenyi, P., et al. (2004). Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. Journal of Acquired Immune Deficiency Syndromes, 36(5), 1100-1102.
82. Palepu, A., Horton, N. J., Tibbetts, N., Meli, S., and Samet, J. H. (2004). Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction, 99(3), 361-368.
83. Paterson, D., Potoski, B., and Capitano, B. (2002). Measurement of adherence to antiretroviral medications. Journal of Acquired Immune Deficiency Syndromes, 31, S103-S106.
84. Paterson, D., Swindells, S., Mohr, J., Brester, M., Vergis, E., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1), 21-30.
85. Pinheiro, C. A., de-Carvalho-Leite, J. C., Drachler, M. L., and Silveira, V. L. (2002). Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: A cross-sectional study in Southern Brazil. Brazilian Journal of Medical and Biological Research, 35(10), 1173-1181.
86. Pradier, C., Carrieri, P., Bentz, L., Spire, B., Dellamonica, P., Moreau, J., et al. (2001). Impact of short-term adherence on virological and immunological success of HAART: A case study among French HIV-infected IDUs. International Journal of STD AIDS, 12(5), 324-328.
87. Raboud, J. M., Harris, M., Rae, S., and Montaner, J. S. (2002). Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Medicine, 3(2), 118-124.
88. Rudd, P. (1979). In search of the gold standard for compliance measurement. Archives of Internal Medicine, 139(6), 627-628.
89. Rudd, P., Ahmed, S., Zachary, Y., Barton, C., Bonduelle, D. (1990). Improved compliance measures: Applications in an ambulatory hypertensive drug trial. Clinical Pharmacology and Therapeutics, 48(6), 676-685.
90. Samet, J. H., Sullivan, L. M., Traphagen, E. T., and Ickovics, J. R. (2001). Measuring adherence among HIV-infected persons: Is MEMS consummate technology? AIDS and Behavior, 5(1), 21-30.
91. Schroder, K. E., Carey, M. P., and Vanable, P. A. (2003). Methodological challenges in research on sexual risk behavior: I. Item content, scaling, and data analytical options. Annals of Behavioral Medicine, 26(2), 76-103.
92. Schuman, P., Ohmit, E., Cohen, M., Sacks, H., et al. (2001). Prescription of and adherence to antiretroviral therapy among women with AIDS. AIDS and Behavior, 5(4), 371.
93. Silveira, M. P., Draschler Mde, L., Leite, J. C., Pinheiro, C. A., and da Silveira, V. L. (2002). Predictors of undetectable plasma viral load in HIV-positive adults receiving antiretroviral therapy in southern Brazil. The Brazilian Journal of Infectious Diseases, 6(4), 164-171.
94. Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F., and Moatti, J. P. (2002). Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients : From a predictive to a dynamic approach. Social Science and Medicine, 54(10), 1481-1496.
95. Straka, R. J., Fish, J. T., Benson, S. R., and Suh, J. T. (1997). Patient self-reporting of compliance does not correspond with electronic monitoring: An evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy, 17(1), 126-132.
96. Trotta, M. P., Ammassari, A., Cozzi-Lepri, A., Zaccarelli, M., Castelli, F., Narciso, P., et al. (2003). Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS, 17(7), 1099-1102.
97. Turner, B. (2002). Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. The Journal of Infectious Disease, 185(Suppl 2), S143-S151.
98. Turner, B. J., and Hecht, F. M. (2001). Improving on a coin toss to predict patient adherence to medications. Annals of Internal Medicine, 134(10), 1004-1006.
99. Vincke, J., Bolton, R. (2002). Therapy adherence and highly active antiretroviral therapy: Comparison of three sources of information. AIDS Patient Care and STDS, 16(10), 487-495.
100. Wagner, G. J. (2002). Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care and STDS, 16(12), 599-608.
101. Wagner, G. J., Kanouse, D. E., Koegel, P., and Sullivan, G. (2003). Adherence to HIV antiretrovirals among persons with serious mental illness. AIDS Patient Care and STDs, 17(4), 179.
102. Wagner, G., and Miller, L. G. (2004). Is the influence of social desirability on patients' self-reported adherence overrated? Journal of Acquired Immune Deficiency Syndromes, 35(2), 203-204.
103. Wagner, J. H., Justice, A. C., Chesney, M., Sinclair, G., Weissman, S., and Rodriguez-Barradas, M. (2001). Patient-and provider-reported adherence: Toward a clinically useful approach to measuring antiretroviral adherence. Journal of Clinical Epidemiology, 54(Suppl 1), S91-S98.
104. Walsh, J. C., Home, R., Dalton, M., Burgess, A. P., and Gazzard, B. G. (2001). Reasons for non-adherence to antiretroviral therapy: Patients' perspectives provide evidence of multiple causes. AIDS Care, 13(6), 709-720.
105. Walsh, J. C., Mandalia, S., and Gazzard, B. G. (2002). Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS, 16(2), 269-277.
106. Waterhouse, D. M., Calzone, K. A., Mele, C., Brenner, D. E. (1993). Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. Journal of Clinical Oncology, 11(6), 1189-1197.
107. Weiser, S., Wolfe, W., Bangsberg, D., Thior, I., Gilbert, P., Makhema, J., et al. (2003). Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal of Acquired Immune Deficiency Syndromes, 34(3), 281-288.
108. Wutoh, A. K., Brown, C. M., Kumoji, E. K., Daftary, M. S., Jones, T., Barnes, N. A., et al. (2001). Antiretroviral adherence and use of alternative therapies among older HIV-infected adults. Journal of the National Medical Association, 93(7-8), 243-250.
109. Wutoh, A., Elekwachi, O., Clarke-Tasker, V., Daftary, M., Powell, N., and Campusano, G. (2003). Assessment and predictors of antiretroviral adherence in older HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes, 33(2), S106-S114.